Deviation Management System
Deviation Management System
Seetha Ram Kotra1#, Rajeswari Ramayanam2, Lavanya Reddy N3#, Sudheer Reddy
Billipelli4#, Ganesh Tsavatapalli1#, Daya Thota5, Sandhya Prathapaneni6# and PVD
Sowjanya Kumari7*
1
Department of Biotechnology, Acharya Nagarjuna University, Guntur – 522510
2
Department of Physics, Acharya Nagarjuna University, Guntur – 522510
3
Department of Biotechnology, The Oxford College of Engineering,
Bangalore – 560068
4
Department of Microbiology, SVS PG College, Kakatiya University,
Warangal – 506009
5
Department of Microbiology, Sri Venkateswara University, Tirupati – 517502
6
Department of Chemistry, Sri Padmavati Mahila Visvavidyalayam,
Tirupati – 517502
7
Department of Microbiology, MVR & PG College, Vishakapatnam – 530026
*[email protected]
Abstract
Production of quality products in biopharmaceutical companies can take up a
principle of scientific, logical, contamination free, risk and impact assessment based
approaches. All product deliverable industries come under Good Manufacturing
Practices (GMP) which will be duly audited by different regulatory agencies across the
world. Identification of instruction which departs from the approved written procedure is
called deviation. End user from user department has to identify the deviation during
manufacturing process and report to QA (Quality Assurance) for further action. After
commenting on deviation by user department head, QA should mark the relevant
departments for their comments on deviation and impact assessment. Based on the
investigation, impact to be assessed and deviation will be classified by QA as minor/
major/ critical. Initial classification of the deviation need not be in inline with final
classification. Appropriate corrective action and preventive action (CAPA) will be
proposed by user department with the co-ordination of relevant cross functional teams
that will be duly verified and approved by QA. CAPA implementation will be carried out
if applicable. Once after initiating the CAPA, deviation will be closed and CAPA
effectiveness will be tracked. This is the first report on industrial deviation practices for
compliance.
1. Introduction
All sterile manufacturers should meet the requirements of current good manufacturing
practices of different regulatory agencies. GMP (Good Manufacturing Practices)
facilitated biopharmaceutical companies are under the category of scientific and risk-
Received (January 17, 2018), Review Result (May 1, 2018), Accepted (May 11, 2018)
#
Authors have equal contribution
*
Corresponding Author
based approaches. This document gives description of procedure for dealing of non
conformance activities during all stages from manufacturing to market complaints.
Concept of the deviation is to document the non conformance and to ensure that all non
conformances are reported and investigated thoroughly to assess the impact on product
quality [1]. Deviation procedure is applicable for developmental/ engineering/ clinical/
pre clinical/ process validation/ commercial batches in best industrial practices [2]. Any
non conformance/ deviating the approved instructions of written procedures are called
deviation.
User department is responsible for the identification, reporting and investigation of the
non conformance. Quality assurance is responsible for the deviation management at all
stages; in view of deviation log in, investigation, review and co-ordination in CAPA
proposal and close out as well. Other cross functional teams will review the deviation
investigation or will involve in the investigation where and when required. National and
international regulatory agencies will review the impact on regulatory requirements of
different markets and on continuous quality improvements [3]. Deviation will be initiated
for any type of wrong entry or entry error or missed entry where supporting documents
are not available. Failing to submission of supporting documents along with batch
manufacturing record or checklist, deviation will be triggered by user department.
4. Types of Deviation
Deviations are of two types based on the event or event to be carried out i.e., planned
and unplanned deviations. In an effective quality management system, all planned and
unplanned deviations will be closed within 30 working days with a window period of 10
working days. For every unplanned critical/ major deviations impact assessment will be
carried out post to activity.
5. Classification
5.1. Critical Deviation
Deviation likely to have significant impact on product quality is called critical
deviation. The following are the examples of critical deviations, but not limited to
i. Operator does not follow critical process parameters during manufacturing.
ii. Usage of unapproved/ expired/ rejected materials in manufacturing.
iii. Printing the wrong batch numbers on labels.
iv. Identifying the data integrity issues.
v. Usage of raw materials in lesser quantities in manufacturing operations/ testing’s.
vi. An observation resulting in a significant risk when used in a finished product.
vii. Batch contamination/ sterility breach
6. Deviation Reporting
All deviation forms should be duly issued by QA upon request by user department
head/ in-charge/ designee and to be documented for review and trending of management
review meeting respectively (Annexure – 1). Further, user department personnel will
write the deviation details including the date of occurrence and along with date of
identification (Annexure – 2). Those details will be reviewed by user department head and
should confirm the noncompliance against standard.
Any non-compliance shall be reported at earliest to QA without any delay. Industries
which are under cGMP (current Good Manufacturing Practices) will report the non
compliance within 24 hours. Deviations will be initiated by initiator or who identifies the
non compliance irrespective of department. During initiation, what is standard and what is
non compliance should be stated clearly along with the reference document number, if
applicable. After observation of non compliance, what immediate corrective action is
taken by user department personnel/ initiator to nullify the impact on product quality
should be stated accurately. If immediate corrective action does not nullify the non-
compliance, then what additional immediate corrective action is taken against to deviation
will be provided along with proper justification. Each and every non compliance, should
be routed through separate deviation including same type of non compliance. But
investigations of similar deviations have to merged in a single investigation. If a
document is erroneous, before initiating, user department personnel/ QA can replace/
demand for the replacement of document by attending the comments. For replacement of
any type of document which is erroneous and was not enrolled in QA records, deviation is
not necessary. Effective quality system should build based on ALCOA (Attributable,
Legible, Contemporaneous, Original and Accurate) or ALCOA+ (Attributable, Legible,
Contemporaneous, Original and Accurate, Complete, Consistent, Enduring and
Available).
non compliance or recurrence of the same or different type. CAPA is the tracking
document or bridging document. CAPA initiation is the responsibility of user department
which initiates deviation and effectiveness of the CAPA to be monitored by user
department with the support of cross functional teams and QA. In case of any delay in
investigation, an extension to the target date should be taken by user department from QA
by using delay justification form (Annexure – 4). All delay justification to be initiated by
on or before the target date for closure. Failing to take delay justification on or before the
target date will trigger a separate deviation and impact assessment for the same to be
mentioned.
Annexure-1
(Deviation management request form)
Annexure-2
Deviation form
Department:
Date of occurrence:
Date of identification:
Date of initiation:
Deviation from: Process /Equipment/ Instrument/ Product/ Utilities/ others
Instrument number/ batch number/ equipment number/ others:
Deviation details in brief:
Deviation identified by (Name):
Deviation reported by (Name, Sign & Date):
Annexure – 3
Deviation management register
S. No:
Date of deviation occurred:
Initiated by department:
Deviation number:
Batch/ Equipment/ Instrument/ Document/ other codes:
Deviation details:
Log in by QA (Name, Sign & Date):
Classification (Critical/Major/Minor)
Impact on product (Yes/No/ NA)
Date of closure:
Closed by Name, Sign& Date:
Verified by Name, Sign & Date:
Remarks:
Annexure – 4
Delay justification form
Quality element: Deviation/ Change control/ OOS (Out Of Specification)/ OOT (Out Of
Trend)/ others
Specify if others:
Deviation/ Change control/ OOS/ OOT/ others number:
Reason/ Justification for delay in closure:
Whether delay has any impact on product quality (Yes/ No/ NA):
Delay: First delay/ Second delay/ Third delay
If first delay, mention the initial committed target date:
If second delay, mention the first target date:
If third delay, mention the second target date:
Next target date:
Name of initiator, Sign& Date:
Reviewed by user department head (Name, Signe & Date):
Approved by QA (Name, Sign & Date):
12. Conclusion
All non conformances during manufacturing process are logged by deviation.
Immediate corrective action is proposed to nullify the impact on product quality. All
deviations are investigated for the proper root cause. Appropriate CAPA is proposed to
avoid the recurrences. Best industrial quality system practice will have all information
furnished above. Deviations will be initiated for system improvements and where impact
assessment on system and product quality is required. An efficient quality management
system does not require deviations for typo errors where supporting documents are
available and which are not impacting process or product quality. In those cases, a clear
justification to be provided by user department head/ in-charge before closure of batch
Acknowledgements
PVD Sowjanya Kumari cordially conveying their regards to Dr. Peravali Jawahar Babu
and Mr. Tanniru Bala Sundara Rao for the information provided.
References
[1] T. Daya, D. Surendra Naidu, N. Lavanya Reddy, K. Seetha Ram and R. Ganapathy, “Current Prospects
of Change Management in Biopharmaceutical Quality Systems – A Holistic Cumulative Review”,
International Journal of Bio-Science and Bio-Technology, vol. 9, no. 5, (2017), pp. 1-12.
[2] https://www.fda.gov/.
[3] http://www.ema.europa.eu/ema/.
Authors